Hengrui Medicine gets green light for clinical trials

Jiangsu Hengrui Medicine (SSE:600276) announced that its subsidiaries have received clinical trial approvals from the National Medical Products Administration for injectable SHR-4602, injectable SHR-A2102, and Atezolizumab injection. The trials will assess SHR-4602 in combination with SHR-A2102, with or without Atezolizumab, in patients with advanced solid tumors. SHR-4602 is designed for HER2-expressing or mutated solid tumors, while SHR-A2102, an anti-Nectin-4 antibody-drug conjugate, targets Nectin-4 expressing tumors. Atezolizumab is an anti-PD-L1 antibody. Hengrui has invested approximately 66.84 million yuan in SHR-4602, 11.907 million yuan in SHR-A2102, and 78.471 million yuan in Atezolizumab injection's related research and development. The company cautioned that the drugs still require clinical trials and regulatory approval before commercialization.